<DOC>
	<DOCNO>NCT01000311</DOCNO>
	<brief_summary>This Phase 3 study design demonstrate safety immunogenicity MenACWY non-interference concomitant routine vaccine MenACWY infant age group .</brief_summary>
	<brief_title>A Study Evaluate Safety Immunogenicity 4 Doses MenACWY Conjugate Vaccine , Administered Concomitantly With Routine Vaccines , Among Infants Aged 2 Months</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>1 . Two monthold infant , born fullterm pregnancy estimate gestational age ≥37 week birth weight ≥2.5 kg . 2 . Documented write informed consent provide parent/legal representative nature study explain . 3 . Parent/legal representative available visit schedule study . 4 . Subjects good health determine : 1. medical history 2. physical assessment 3. clinical judgment investigator 1 . Subjects previously receive meningococcal vaccine vaccine diphtheria , tetanus , pertussis , polio ( IPV OPV ) , H. influenzae type b ( Hib ) pneumococcus . Exceptions : prior dos HBV vaccination ( one two dos ) permit . 2 . Subjects previous confirm suspected disease cause N. meningitidis , C. diphtheriae , C. tetani , poliovirus , Hepatitis B , Hib , pneumococcus B. pertussis ( history laboratory confirm , clinical condition paroxysmal cough period longer equal 2 week associate apnea whoop ) . 3 . Subjects household contact and/or intimate exposure individual laboratory confirm N. meningitidis , B. pertussis , Hib , C. diphtheriae , polio , pneumococcal infection time since birth . 4 . Subjects history anaphylactic shock , asthma , urticaria allergic reaction previous vaccination know hypersensitivity vaccine component . 5 . Subjects experience significant acute chronic infection within previous 7 day experience fever ( temperature ≥ 38.0°C [ 100.4°F ] ) within previous 3 day . 6 . Subjects serious acute chronic disease , neurological disease include seizure , congenital defect , cytogenic disorder ( e.g. , Down syndrome ) . 7 . Subjects know suspected autoimmune disease persistent impairment/alteration immune function . 8 . Subjects suspect known HIV infection born mother know HIV positive . 9 . Subjects ever receive blood , blood product and/or plasma derivative parenteral immunoglobulin preparation ( include Hepatitis B immune globulin ) . 10 . Subjects know bleed diathesis , condition may associate prolonged bleeding time . 11 . Subjects parents/legal representative plan leave area study site end study period . 12 . Subjects condition , opinion investigator , might interfere evaluation study objective . 13 . Subjects receive investigational agent vaccine since birth expect receive investigational agent vaccine prior completion study . 14 . Subjects relatives site research staff work study .</criteria>
	<gender>All</gender>
	<minimum_age>55 Days</minimum_age>
	<maximum_age>89 Days</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>MenACWY conjugate vaccine infant</keyword>
	<keyword>Meningococcal vaccine infant</keyword>
	<keyword>MenACWY</keyword>
</DOC>